What one share of MiNK Therapeutics holds
MiNK Therapeutics, Inc. (“we,” “our,” or “MiNK”) is focused on developing innovative treatments for cancer and immune-mediated diseases using allogeneic, ex-vivo expanded invariant natural killer T ("iNKT") cells. Amid a broader industry renaissance in innate immunity—highlighted by surging investment and clinical activity in NK, γδ T, and iNKT-based therapies—iNKT cells represent a distinct T cell (“T”) population that uniquely bridges innate and adaptive immunity.
MiNK Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$2.40 |
|---|---|
| Cash and investments | $1.73 |
| Book value | −$2.75 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | — | −$6.74 | $0.04 | −$3.50 | — | −$22.28 |
| 2021 | — | −$11.61 | $0.10 | −$5.02 | — | $7.10 |
| 2022 | — | −$8.31 | $0.07 | −$5.68 | — | −$0.12 |
| 2023 | — | −$6.54 | $0.02 | −$4.61 | — | −$5.22 |
| 2024 | — | −$2.86 | — | — | — | −$4.94 |
| 2025 | — | −$2.93 | — | — | — | −$3.02 |
Common questions about MiNK Therapeutics
How much does one share of MiNK Therapeutics earn?
Over the last 12 months, MiNK Therapeutics lost $2.40 for each share.
Does MiNK Therapeutics pay a dividend?
MiNK Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is MiNK Therapeutics’s book value per share?
MiNK Therapeutics’s book value is negative (−$2.75 per share): it owes more than everything it owns is recorded at, often after years of buying back its own shares, as of June 30, 2026.
How much cash and debt does each share of MiNK Therapeutics have?
Each share of MiNK Therapeutics has $1.73 of cash and investments, as of June 30, 2026.
Has MiNK Therapeutics bought back shares?
MiNK Therapeutics’s share count rose about 77% from 2020 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.